Potential First-in-Class, Liver-Selective Glucokinase Activator HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at the 56th Annual Meeting of the European […]